Additional Ring Containing Patents (Class 514/317)
  • Patent number: 10357458
    Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 23, 2019
    Assignee: Signpath Pharma Inc.
    Inventor: Lawrence Helson
  • Patent number: 10238642
    Abstract: The invention relates to methods for treating neurogenic orthostatic hypotension and symptoms thereof using 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: March 26, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: Sharathchandra S. Hegde
  • Patent number: 10226454
    Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: March 12, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Robert S. Chao, Miroslav Rapta
  • Patent number: 10214514
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: February 26, 2019
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Patent number: 10183025
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 22, 2019
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Le Grand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • Patent number: 10111860
    Abstract: Compositions and methods for mitigating a pathology following brain trauma or at least a portion of a cascade of a pathology associated therewith, including compositions and methods for treating concussion or preventing the onset of anecrotic cell death in neurons. Exemplary compositions for treating concussion include an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and one or more pharmaceutically acceptable excipients. The one or more excipients can be combined with the active compound to form an extended, controlled-release medicament that delivers a therapeutic concentration of the active compound over a period of time.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 30, 2018
    Inventor: Robert E. Becker
  • Patent number: 10047049
    Abstract: This invention provides a pridopidine base in a solid form, a method of preparing the solid pridopidine base, and a composition comprising the pridopidine base including a pharmaceutical composition.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 14, 2018
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Offir Barel, Ramy Lidor-Hadas, Ronen Gottesfeld, Orel Yosef Mizrahi, Anders Olof Ingemar Bergh, Ba-Vu Nguyen
  • Patent number: 10029997
    Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 24, 2018
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mouad Edderkaoui, Ramachandran Murali, Stephen Pandol
  • Patent number: 9988375
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: June 5, 2018
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 9944644
    Abstract: The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • Patent number: 9855225
    Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: January 2, 2018
    Assignee: TEMPLE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER
    Inventors: Toby K. Eisenstein, Rebecca R. Hartzell, Martin W. Alder, Joseph J. Meissier
  • Patent number: 9809540
    Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 7, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Francis Dominic Sanderson, Sarah Mary Vallance
  • Patent number: 9708299
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 18, 2017
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Patent number: 9708253
    Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu, Carolyn A. Weigelt
  • Patent number: 9675603
    Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-? suitable for oral dosage to treat subjects having PPAR-? mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-? mediated condition.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 13, 2017
    Assignee: InteKrin Therapeutics, Inc.
    Inventors: Kathleen M. Lee, Linda Higgins, Dennis Lanfear
  • Patent number: 9675599
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 13, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Patent number: 9662308
    Abstract: The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 30, 2017
    Assignee: Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG
    Inventors: Bernd Clement, Joscha Kotthaus, Jürke Kotthaus, Dennis Schade
  • Patent number: 9603844
    Abstract: The present invention provides methods of inhibiting abnormal growth of cells, with the methods comprising contacting the cells with at least one of the sensitizing compounds disclosed herein in an amount sufficient to inhibit cell growth. The present invention also provides methods of treating and/or reducing the likelihood of being diagnosed with breast cancer, with the methods comprising administering to a subject in need of treatment thereof at least one of the sensitizing compounds disclosed herein.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 28, 2017
    Assignee: Georgetown University
    Inventors: Eliot M Rosen, York A Tomita
  • Patent number: 9580810
    Abstract: The present invention aims to provide a method for producing a dispersion of metal nanoparticles which enables to control the shape and the particle diameter over a wide range, a dispersion of metal nanoparticles having superior dispersion stability, and a method for producing the same. In addition, the present invention further aims to provide a dispersion of metal nanoparticles which has a volume resistivity of 2×10?6 to 6×10?6 ?·cm and is suitable for use as an electrically conductive material, and a method for producing the same. Moreover, the present invention further aims to provide a method for synthesizing metal nanoparticles which can produce metal nanoparticles suitable for use as electrically conductive materials by synthesizing the metal nanoparticles from a insoluble metal salt which is free of corrosive materials.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: February 28, 2017
    Assignee: Mitsubishi Materials Corporation
    Inventors: Kazuhiko Yamasaki, Airi Katagiri, Masahide Arai, Yoshiaki Takata, Toshiharu Hayashi
  • Patent number: 9580811
    Abstract: The present invention aims to provide a method for producing a dispersion of metal nanoparticles which enables to control the shape and the particle diameter over a wide range, a dispersion of metal nanoparticles having superior dispersion stability, and a method for producing the same. In addition, the present invention further aims to provide a dispersion of metal nanoparticles which has a volume resistivity of 2×10?6 to 6×10?6 ?·cm and is suitable for use as an electrically conductive material, and a method for producing the same. Moreover, the present invention further aims to provide a method for synthesizing metal nanoparticles which can produce metal nanoparticles suitable for use as electrically conductive materials by synthesizing the metal nanoparticles from a insoluble metal salt which is free of corrosive materials.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: February 28, 2017
    Assignee: Mitsubishi Materials Corporation
    Inventors: Kazuhiko Yamasaki, Airi Katagiri, Masahide Arai, Yoshiaki Takata, Toshiharu Hayashi
  • Patent number: 9511070
    Abstract: Methods, uses, medicaments, and unit doses for treating viral diseases are described herein. The methods, uses, medicaments, and unit doses include (a) substituted piperidine and piperazine carboxamides, or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable carriers, excipients or diluents, or combinations thereof. Viral diseases include hepatitis C virus, HIV, BVDV, and Coronavirus infections.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: December 6, 2016
    Assignee: NovaDrug, LLC
    Inventor: Eliezer Huberman
  • Patent number: 9446029
    Abstract: Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with volatile anesthetics for general anesthesia.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 20, 2016
    Assignee: Colorado State University Research Foundation
    Inventors: Pedro Boscan, David Twedt
  • Patent number: 9427479
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 30, 2016
    Assignee: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 9409893
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: August 9, 2016
    Assignee: Jacobus Pharmaceutical Company, Inc.
    Inventors: Gavin David Heffernan, David Penman Jacobus, Kurt William Saionz, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Patent number: 9375421
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 28, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9303249
    Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 5, 2016
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventors: Kenneth Valenzano, John Crowley, Richie Khanna, John Flanagan
  • Patent number: 9212180
    Abstract: The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, VANDERBILT UNIVERSITY
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Sunil Kumar Upadhyay, Shaun R. Stauffer, Rocco D. Gogliotti, Timothy J. Senter
  • Patent number: 9162982
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 20, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • Patent number: 9139523
    Abstract: The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT2B receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: September 22, 2015
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Johannes Wilhelmus John F. Thuring, Luc August Laurentius Ver Donck
  • Patent number: 9139525
    Abstract: A compound having the general formula wherein A is selected from the group consisting of to the formation of a compound of the general formula (1) and a compound of the general formula (2) respectively, and pharmaceutically acceptable salts thereof, wherein R1 is a member selected from the group consisting of CF3, OSO2CF3, OSO2CH3, SOR4, SO2R4, COR4, CN, OR4, NO2, CONHR4, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br and I, wherein R4 is as defined below; R2 is a member selected from the group consisting of H, F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, NH2, SOmCF3, O(CH2)mCF3, SO2N(R4)2, CH?NOR4, COCOOR4, COCOON(R4)2, (C1-C8)alkyl, (C3-C8)cykloalkyl, CH2OR4, CH2(R4)2, NR4SO2CF3, NO2, at phenyl at positions 2, 4, 5 or 6, wherein x and R4 are as defined below; R3 is a member selected from the group consisting of hydrogen, CF3, CH2CF3, (C1-C8)alkyl, (C3-C8)cykloalkyl, (C4-C9)cycloalkylmethyl, (C2-C8)alkenyl, (C2-C8)alkynyl, 3,3,3-tri-fluoropropyl, 4,4,4-trifluorobutyl, CH2SCH3, CH2CH2OCH
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: September 22, 2015
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventor: Håkan V. Wikström
  • Patent number: 9125407
    Abstract: This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: September 8, 2015
    Assignee: MERIAL, INC.
    Inventor: Charles Q Meng
  • Patent number: 9078865
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: July 14, 2015
    Assignee: Baylor College of Medicine
    Inventor: Brendan Lee
  • Patent number: 9072772
    Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: July 7, 2015
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
  • Patent number: 9073859
    Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: July 7, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Robert S. Chao, Miroslav Rapta
  • Publication number: 20150148318
    Abstract: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 ?M concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Patent number: 9040082
    Abstract: Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 26, 2015
    Inventor: Jon D. Kaiser
  • Publication number: 20150141380
    Abstract: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 21, 2015
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mark A. Smith, Michael Snape
  • Patent number: 9034902
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150133297
    Abstract: The present invention relates to new antifungal compositions and their use in the treatment of agricultural products.
    Type: Application
    Filed: April 25, 2013
    Publication date: May 14, 2015
    Inventors: Jacobus Stark, Eva Louise Wilhelmine Sack
  • Publication number: 20150125493
    Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 7, 2015
    Applicant: ALZA CORPORATION
    Inventors: SUNEEL K. GUPTA, DIANE R. GUINTA, CAROL A. CHRISTOPHER, SAMUEL R. SAKS, LAWRENCE G. HAMEL
  • Publication number: 20150126511
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 7, 2015
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPBELL
  • Publication number: 20150125521
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 7, 2015
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9023389
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: May 5, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150118302
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118300
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118301
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 4, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118285
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 30, 2015
    Inventors: Gilles H. Tapolsky, David W. Osborne
  • Publication number: 20150118295
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9018200
    Abstract: Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: April 28, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Milana Maletic, Harold B. Wood, Wanying Sun
  • Publication number: 20150110868
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 23, 2015
    Inventors: David Lickrish, Feng Zhang